My 10 Top Stocks to Buy to Start the New Year Off Right

Markets entered the year having posted double-digit gains and the piece highlights optimism that AI adoption and Federal Reserve rate cuts could support further equity performance. The author recommends ten high-conviction names — notable specifics include Eli Lilly’s tirzepatide blockbusters and removal of a shortage plus Medicare coverage for a sleep-apnea indication (Goldman Sachs sees an obesity market up to $130B by 2030), Nvidia’s >70% gross margin and ~140% trailing-year share gain, CrowdStrike’s ARR topping $4B with $153M added in the quarter, CRISPR Therapeutics’ first approval for Casgevy and ~40 patients treated, Chewy’s debt-free balance sheet with ~$1.3B liquidity, Amazon’s AWS reaching a $110 annual revenue run rate, and the SPDR S&P 500 ETF’s 0.09% expense ratio as a diversified alternative.

Analysis

Market structure: The apparent winners are AI infrastructure and platform plays (NVDA, AMZN, META, CRM) plus niche medical winners with regulatory momentum (LLY, CRSP, ISRG). These companies gain pricing power and recurring-revenue leverage (GPU rents, AWS/ads, SaaS ARR, device consumables), while low-margin incumbents and non-AI-dependent retailers face share and margin pressure. Expect revenue concentration: top 5–10 AI suppliers will capture a disproportionate share of enterprise AI spend over 12–36 months, tightening supply/demand for high-end GPUs and cloud capacity.

Risk assessment: Key tail risks are regulatory (antitrust/AI safety, drug-pricing reforms) and operational (chip supply constraints, CRISPR reimbursement delays). Time horizons: immediate (0–60 days) for earnings/approval headlines, short-term (3–9 months) for Fed-driven multiple expansion or compression, and long-term (12–36 months) for durable AI monetization. Hidden dependencies include OEM supply chains for NVDA and Medicare/pricing rules for LLY/CRSP; a single negative policy move could shave 20–40% off consensus fair values for exposed names.

Trade implications: Overweight differentiated AI exposures and durable recurring revenue SaaS; underweight discretionary/low-repeat retail. Use asymmetric option structures: buy 12–18 month LEAP calls on NVDA/AMZN to capture convexity, paired with 3–6 month SPY puts sized to 1–2% portfolio as tail-hedge. Execute relative-value pairs (long CRM vs short CHWY) to capture enterprise AI reallocation while hedging beta to the market.

Contrarian angles: The market underestimates concentration risk—NVDA dominance is vulnerable to supply shocks or a faster competitor roadmap; obesity/CRISPR winners may face adverse reimbursement surprises despite approvals. Valuations may be pricing near-perfect execution; prefer staged entries (scale in over 10–30% price moves) and size positions so a single regulatory catalyst cannot exceed 3% portfolio risk.

Key Decisions for Investors

• Establish a 1.5–2.0% portfolio long position in NVDA via 12–18 month LEAP calls (target delta ~0.35–0.45) to capture AI infrastructure upside; set a time-based profit target of +40–60% at 12 months and a hard stop at -25% from entry.
• Allocate 1.0% each to AMZN and META via 6–12 month debit call spreads (buy near‑ATM, sell 10–20% OTM) to limit premium outlay; trim positions if company-specific revenue guidance misses by >3 percentage points or if ad/AI spend growth decelerates sequentially two quarters.
• Initiate a cautious biotech sleeve: 1.0% long LLY and 0.5% long CRSP in equity size, but only after monitoring Medicare/pricing guidance and any CRISPR reimbursement announcements over the next 30–60 days; if negative policy headlines cause a >10% price drop, add an incremental 50% to each position.
• Implement portfolio protection and relative-value trades: buy 3–6 month SPY puts ~5% OTM sized to 1–2% portfolio as near-term insurance, and enter a pair trade long CRM (1.5% portfolio) vs short CHWY (1.5%) to express rotation into enterprise AI spend while hedging market beta; re-evaluate after two quarterly earnings releases.